Latest news about Biogen Pharmachem
Biogen Pharmachem
0.34
-0.02(-5.56%)
Company Performance:
View Company Insights1D-5.56%
1M-15.00%
6M-46.03%
1Y-59.04%
5Y+78.95%
More news about Biogen Pharmachem
01Apr 26
Biogen Pharmachem Industries Sets Record Date for 1:6 Bonus Share Issuance
Biogen Pharmachem Industries Limited has set May 15, 2026, as the record date for its 1:6 bonus share issuance, where shareholders will receive 1 new equity share of Rs.1/- for every 6 existing shares. The proposal requires shareholder approval via postal ballot and e-voting, with the company maintaining full regulatory compliance under SEBI LODR requirements.
27Mar 26
Biogen Pharmachem Announces Postal Ballot for 1:6 Bonus Share Issue and Capital Increase
Biogen Pharmachem Industries Limited has issued a comprehensive postal ballot notice for shareholder voting on major corporate actions including a 1:6 bonus share issue creating 15,04,33,833 new shares, authorized capital increase from Rs. 91,00,00,000 to Rs. 1,08,00,00,000, and appointment of M/s. Goenka Mehta & Associates as statutory auditors. The e-voting period runs from March 27 to April 25, 2026, with results expected by April 27, 2026.
24Feb 26
Biogen Pharmachem: Company Plans To Review Bonus Share Issue On March 23
Biogen Pharmachem Industries Limited has announced a board meeting scheduled for March 23, 2026, to consider the declaration of bonus shares. The meeting will be held at the company's registered office and follows SEBI (LODR) Regulations, 2015 compliance requirements. The proposed bonus share issuance remains subject to shareholder approval and represents a potential value addition for existing shareholders.
19Jan 26
Biogen Pharmachem Industries Limited Schedules Board Meeting for February 3, 2026 to Consider Q3FY26 Financial Results
Biogen Pharmachem Industries Limited has scheduled a board meeting for February 3, 2026, to approve Q3FY26 unaudited financial results for the quarter and nine months ended December 31, 2025. The company notified BSE Limited about this meeting in compliance with SEBI (LODR) Regulations, 2015, with the formal communication signed by Director Kelash Bunkar on January 19, 2026.
05Jan 26
Biogen Pharmachem Industries Submits Q3FY26 SEBI Compliance Certificate
Biogen Pharmachem Industries Limited submitted its Q3FY26 compliance certificate under SEBI Regulation 74(5) on January 5, 2026, covering the quarter ended December 31, 2025. The certificate, issued by registrar Satellite Corporate Services Private Limited, confirms no physical share certificates were received for dematerialization during the quarter, maintaining regulatory transparency for the BSE-listed pharmaceutical company.
23Jul 25
Biogen Pharmachem Industries Reports Impressive Turnaround with Rs 134.48 Lakh Net Profit in Q1
Biogen Pharmachem Industries Limited has reported a significant financial turnaround in Q1. The company's net profit rose to Rs 134.48 lakhs, compared to a loss of Rs 15.83 lakhs in the same quarter last year. Revenue from operations increased to Rs 154.28 lakhs from a negative Rs 9.09 lakhs. Total expenses increased to Rs 19.80 lakhs. The company's paid-up equity share capital rose to Rs 9,026.03 lakhs. Auditors found no issues with the financial results.
Industry Peers
Spice Lounge Food Works
Algoquant Fintech
LKP Finance
Kalind
Wealth First Portfolio Managers
Prime Securities
RNFI Services
Investment Trust of India
NDL Ventures
Corporate Merchant Bankers
24.65
(+1.48%)
54.75
(-1.72%)
188.00
(+2.90%)
93.12
(+2.09%)
935.90
(-0.04%)
276.60
(-0.74%)
258.75
(-0.60%)
97.63
(-1.30%)
130.32
(-2.41%)
59.63
(+4.71%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
